Cubist Systematic Strategies, LLC Cellectis S.A. Transaction History

Cubist Systematic Strategies, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$7.81 - $18.82 $16,072 - $38,731	-2,058 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$9.73 - $19.31 $15,071 - $29,911	-1,549 Reduced 42.94%	2,058 $35,000
Q3 2019 Nov 14, 2019	SELL	$10.15 - $16.89 $30,389 - $50,568	-2,994 Reduced 45.36%	3,607 $38,000
Q2 2019 Aug 14, 2019	BUY	$14.6 - $20.6 $96,374 - $135,980	6,601 New	6,601 $103,000
Q4 2018 Feb 14, 2019	SELL	$15.58 - $28.41 $26,704 - $48,694	-1,714 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$25.99 - $30.6 $44,546 - $52,448	1,714 New	1,714 $48,000
Q2 2018 Aug 14, 2018	SELL	$27.78 - $38.53 $26,335 - $36,526	-948 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$27.78 - $35.19 $26,335 - $33,360	948 New	948 $30,000

10.8M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $71M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.